BioPharmSignal logoBioPharmSignal

Biotech News

Alkermes to Present at Upcoming Investor Conferences

Alkermes plc (ALKS)Alkermes plcConference / presentation

DUBLIN --(BUSINESS WIRE)--Nov. 3, 2026-- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2026 Healthcare Conference Date/Time: Fireside chat on Tuesday, Nov. 10, 2026 at 10:40 a.m. ET ( 3:40 p.m.

Related news

NBIXNeurocrine Biosciences2026-09-02 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

GANXGain Therapeutics2026-11-05 12:00 EST

Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences

KTTAPasithea Therapeutics2026-09-03 20:05 EST

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

TNXPTonix Pharmaceuticals2026-11-04 12:00 EST

Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference

XENEXenon2026-09-03 20:01 EST

Xenon to Present at Wells Fargo Healthcare Conference

ALKSAlkermes plc2026-11-03 12:05 EST

Alkermes plc Reports Third Quarter 2026 Financial Results

ALKSAlkermes plc2026-10-30 11:00 EST

Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)

NERVMinerva Neuroscience2026-10-29 11:00 EST

Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

RVPHReviva Pharmaceuticals2026-09-22 12:00 EST

Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference

GANXGain Therapeutics2026-09-17 11:00 EST

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

View all latest news

Alkermes plc

Alkermes is a biopharmaceutical company focused on neuroscience, addiction medicine, and specialty therapeutics. Its portfolio combines commercial products and development programs across CNS and related areas.

Recent company news

ALKSAlkermes plc2026-11-05 12:00 EST

Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress

ALKSAlkermes plc2026-11-03 21:00 EST

Alkermes to Present at Upcoming Investor Conferences

ALKSAlkermes plc2026-11-03 12:05 EST

Alkermes plc Reports Third Quarter 2026 Financial Results

ALKSAlkermes plc2026-10-30 11:00 EST

Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)

ALKSAlkermes plc2026-10-20 20:00 EST

Alkermes to Report Third Quarter Financial Results on November 3, 2026

Stock data

Close
44.54 USD
Market cap
6.89B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States